Literature DB >> 15790486

Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis.

Wendy Lawley1, Heather Hird, Philip Mallinder, Sue McKenna, Beverley Hargadon, Alistair Murray, Peter Bradding.   

Abstract

A well-characterised gain-of-function point mutation within exon 17 of the c-kit proto-oncogene known as Asp816Val is present in patients with mastocytosis. Activation of mast cells through this receptor primes them for IgE-dependent activation, and patients with mastocytosis are at increased risk of anaphylaxis. We hypothesised that the Asp816Val mutation is associated with a history of anaphylaxis in the general population. A mismatch amplification real-time PCR assay was developed and validated to test for the Asp816Val mutation. Subjects were recruited to four subject groups: normal non-atopics, atopics without anaphylaxis, food-induced anaphylactics and non-food anaphylactics. Blood samples collected from forty subjects were tested for the presence of Asp816Val. Thirteen subjects were found to carry the mutation; normals (2/9), atopics (2/10), food anaphylactics (5/11) and non-food anaphylactics (4/10). Statistical analysis of the data determined that there was no significant difference between the numbers of subjects found to carry the Asp816Val mutation in each of the groups although a trend towards an increased occurrence in anaphylactics was observed. In summary, the hypothesis that the presence of the Asp816Val mutation is linked to the occurrence of anaphylaxis was not supported, but interestingly, we have shown for the first time Asp816Val may occur more frequently than previously reported within the general population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790486     DOI: 10.1016/j.mrfmmm.2004.08.015

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  5 in total

Review 1.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Cem Akin
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

2.  Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.

Authors:  Lina Han; Jan Jacob Schuringa; André Mulder; Edo Vellenga
Journal:  Ann Hematol       Date:  2010-04-13       Impact factor: 3.673

Review 3.  Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.

Authors:  B M Jensen; C Akin; A M Gilfillan
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

Review 4.  Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.

Authors:  Gerhard J Molderings; Stefan Brettner; Jürgen Homann; Lawrence B Afrin
Journal:  J Hematol Oncol       Date:  2011-03-22       Impact factor: 17.388

5.  Detection of clonal mast cell disease in wasp venom allergic patients with normal tryptase.

Authors:  Merel C Onnes; Abdulrazzaq Alheraky; Martijn C Nawijn; Tim E Sluijter; André B Mulder; Suzanne Arends; Hanneke N G Oude Elberink
Journal:  Clin Transl Allergy       Date:  2022-09-07       Impact factor: 5.657

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.